Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Clinicians and care teams are increasingly focused on GLP‑1 receptor agonists, but SGLT2 inhibitors and metformin in diabetes management remain foundational in achieving comprehensive, evidence‑based outcomes. While GLP‑1 therapies generate headlines for weight loss and glucose control, 2025 guidelines still strongly emphasize the cardioprotective and renoprotective benefits of SGLT2 inhibitors …
Read More »Beyond GLP‑1s: Are We Overlooking the Role of SGLT2 Inhibitors and Metformin?
